Investors & Media

News

March 22, 2022

Sage Therapeutics to Present at 2022 Stifel CNS Days

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 22, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will give a presentation at the 2022 Stifel CNS Days on Tuesday, March 29, 2022 at 4:00pm ET.

A live webcast of the presentation can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.

Investor Contact
Helen Rubinstein
315-382-3979
helen.rubinstein@sagerx.com

Media Contact
Becky Kern
914-772-2310
becky.kern@sagerx.com

Source: Sage Therapeutics, Inc.